**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 61883

**Manuscript Type:** REVIEW

**Cascade of care for children and adolescents with chronic hepatitis C**

Rogers ME *et al*. Chronic hepatitis C in children

Michael Evan Rogers, William F Balistreri

**Michael Evan Rogers, William F Balistreri,** Department ofPediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45209, United States

**Author contributions:** Rogers ME is the first author; Balistreri W is the lead and corresponding author; all authors helped in research, write, and edit the final review manuscript.

**Corresponding author: William F Balistreri, FAASLD, MD, Doctor,** Department ofPediatrics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, United States. william.balistreri@cchmc.org

**Received:** December 21, 2020

**Revised:** January 19, 2021

**Accepted:** March 11, 2021

**Published online:**

**Abstract**

Chronic hepatitis C virus (HCV) infection presents a significant global public health burden. In 2015, over 400000 deaths worldwide were attributed to HCV infection. This led the World Health Organization (WHO) in 2016 to set the ambitious goal of eliminating HCV by 2030. Adult-centered guidelines have been established in order to provide direction for healthcare professionals, allowing integration of the newest screening policies and therapeutic strategies into their practices. However, for children and adolescents, HCV is a significant, unrecognized public health problem. HCV infection rates in the United States in women of childbearing age and those who are pregnant have increased in parallel with the rising opioid epidemic. An estimated 29000 women with HCV infection gave birth each year from 2011 to 2014 in the United States, with approximately 1700 of their infants being infected with HCV. Newer HCV-specific therapeutics, namely direct acting antivirals (DAA), has brought a new and highly successful approach to treatment of hepatitis C. Recent studies have confirmed similar levels of effectiveness and safety of DAA therapies in the pediatric population. Thus, an enhanced cascade of care, which should include the population under 18 years of age, can help achieve the WHO goal by focusing on elimination in the youngest populations. This review will present an overview of the natural history, clinical features, and management of HCV in children and adolescents.

**Key Words:** Hepatitis C virus; Hepatitis C education; Hepatitis C elimination

Rogers ME, Balistreri WF. Cascade of care for children and adolescents with chronic hepatitis C. *World J Gastroenterol* 2021; In press

**Core Tip:** In 2020, the landmark series of accomplishments which started with the discovery of the hepatitis C virus (HCV) and led to the development of pharmaceutical agents capable of curing HCV infection was underscored by the awarding of the Nobel Prize in Medicine. This innovative cure is now being applied to the pediatric population. Furthermore, programs such as The Kentucky Hepatitis Academic Mentorship Program have been developed to train general pediatricians on HCV epidemiology, diagnosis, management, treatment and prevention. Thus this cascade of care will hopefully help achieve the World Health Organization goal of eliminating HCV by 2030.

**INTRODUCTION**

The arc of discovery–from identification of the hepatitis C virus (HCV) as the causative agent of what was termed “Non-, Non-B Hepatitis” in 1989 to the development of pharmaceutical agent capable of efficiently curing HCV infection was remarkably short. In October 2020, this landmark series of accomplishments was underscored by the awarding of the Nobel Prize in Medicine to Drs. Alter, Houghton, and Rice. The Nobel committee recognized that their work transformed molecular virology/immunology and revolutionized the management of infected patients worldwide[1,2].

HCV infection presents a significant global public health burden. It is currently estimated that over 70 million individuals are chronically infected with HCV and that many are unaware of their infectious status[3]. In 2015, over 400000 deaths worldwide were attributed to HCV infection. This led the World Health Organization (WHO) in 2016 to set the ambitious goal of eliminating HCV by 2030. Despite the advances in HCV therapeutics, significant cost and access to care are the major barriers to the achievement of this goal[4].

Adult-centered guidelines have been established in order to provide direction for healthcare professionals, allowing integration of the newest screening policies and therapeutic strategies into their practices. For children and adolescents, HCV is a significant, unrecognized public health problem. Perinatal transmission accounts for the majority of recognized HCV infections in the pediatric population. HCV infection rates in the United States in women of childbearing age and those who are pregnant have increased in parallel with the rising opioid epidemic. An estimated 29000 women with HCV infection gave birth each year from 2011 to 2014 in the United States, with approximately 1700 of their infants being infected with HCV[5].

Newer HCV-specific therapeutics, namely direct acting antivirals (DAA), have brought a new and highly successful approach to treatment of hepatitis C. Recent studies have confirmed similar levels of effectiveness and safety of DAA therapies in the pediatric population. Thus, an enhanced cascade of care, which should include the population under 18 years of age, can help achieve the WHO goal by focusing on elimination in the youngest populations.

This review will present an overview of the natural history, clinical features, and management of HCV in children and adolescents.

**Epidemiology of Hepatitis C**

All 6 HCV genotypes have been diagnosed in the pediatric population; based on limited reporting, the genotypic distribution appears to mimic what is seen in the adult population, with genotype 1 predominating[6].

HCV infection is most often asymptomaticin the pediatric population; therefore, it is difficult to estimate the true global prevalence. Schmelzer *et al*[7] combined past modelling and epidemiological work in 104 countries and territories to estimate the prevalence in children in 2018. They reported the global estimated viremic prevalence in the population under 18 years of age to be 0.13%, corresponding to 3.26 million children with HCV in 2018, with wide variability. The prevalence increased with age in all countries and territories. The strongest predictor of HCV prevalence in children aged 0-4 years was the HCV prevalence in women of childbearing age. The proportion of HCV infections in adults who inject drugs was significantly associated with HCV prevalence in children aged 15-19 years[8]. In view of the wide heterogeneity, reliable country- or territory-specific and age-specific HCV prevalence estimates will be required in order to allow countries and territories to improve national HCV elimination and treatment strategies.

The true prevalence of pediatric HCV infection in the United States is also unknown due to a lack of uniform screening strategies. In 2020, the United States Preventive Services Task Force (USPSTF) issued revised recommendations that encourages clinicians to screen all adults aged 18 to 79 years for HCV infection[9]. Previously, they had expressed a concern that HCV screening might be associated with negative psychological and social consequences. However, treatment with DAA therapy has been associated with improved quality of life in addition to high rates of curing HCV[10]. Thus, as screening tests for HCV are highly accurate, they now conclude that the combination of screening with DAA therapy indicates improved long-term outcomes.

The USPSTF recommendations specifically suggest HCV screening for all pregnant women during each pregnancy. This is important since therate of HCV infection in pregnant women has continued to increase, with an associated increase in the number of infants exposed to HCV.

The risk of perinatal transmission is confined to HCV infected women who have detectable HCV RNA. The risk of transmission is increased with higher levels of HCV viremia, as well as co-infection with HIV[11-14]. The mode of delivery (vaginal *vs* cesarean-section) does not typically affect risk of transmission[13]. However, if the mother is co-infected with HIV, then there may be a protective affect by undergoing a cesarean-section for delivery[11]. HCV RNA may be detected in breast milk and colostrum, however breast feeding does not appear to increase the rate of HCV transmission (with the exception of HIV co-infected mothers)[15].

While prenatal care settings are potential venues for expanding HCV testing, implementation is sporadic. Epstein *et al*[8] characterized the HCV diagnostic cascade for women attending an obstetric clinic serving individuals with substance use disorders. They reported successfully screening for HCV among pregnant women with opioid use. In retrospective cohort study of infants exposed to HCV who were enrolled in the Tennessee Medicaid program, testing was conducted in only 23% of infants and less frequently among African American infants[16]. These two observations indicate that infant HCV screening is currently imperfect, emphasizing the need for programmatic changes to improve both mother and infant follow-up to bridge gaps in the cascade to cure. Because current testing recommendations may not properly address the barriers to HCV testing among high-risk infants, contributing to missed HCV infections, new policies (such as universal pediatric testing) may address the gaps[6,17,18].

Screening in adolescents may also be improved. Epstein *et al*[19] reported that only 30% of adolescentswith identified opioid, amphetamine, or cocaine use were tested for HCV; 7% were found to be positive.Barritt *et al*[20] reported that in the United States from 2006-2012, the hospitalization rates of children with HCV increased by 37%; the majority of these patients were adolescents. This further reflects that our attempts at identifying and treating HCV in early childhood and adolescents are inadequate.

**Natural History**

Children with chronic HCV infection are typically asymptomatic[6,17]. An estimated 20%-40% will undergo spontaneous clearance within the first 5 years of life[21,22]. A combination of perinatal transmission and genotype 1a is associated with decreased rates of clearance, persistent viremia, and higher likelihood of development of end-stage liver disease in children who are treatment naïve[23]. Albeit uncommon, progression to cirrhosis has been described and hepatocellular carcinoma (HCC) secondary to HCV and cirrhosis in a child has also been reported[24].

Younossi *et al*[25] reported that HCV infection in adolescents was associated with poor social functioning and health-related quality of life (HRQoL). Children chronically infected with HCV had a significant reduction in a wide range of intelligence and memory testing. Vocabulary, reading comprehension, abstract visual reasoning, and short-term memory were all statistically inferior in HCV infected children compared to healthy controls[26]. Treatment of HCV led to improved quality of life, using multiple validated patient reported outcome instruments[25].Therefore, while the liver disease in HCV infected children is often absent or mild, treatment may lead to improved HRQoL in addition to prevention of cirrhosis and end-stage liver disease.

**Clinical Features and Outcomes**

Jaundice, fatigue, dyspepsia, and abdominal pain are the most common signs and symptoms reported in adults[27]. Unfortunately, there is less robust prospective data regarding clinical symptoms in children and adolescents. When reported, minimal nonspecific and brief symptoms are found in approximately 15% of children. These symptoms can be in the form of fatigue, anorexia, nausea, vomiting, and abdominal colic[28].

Extrahepatic manifestations of HCV infection are well documented in the adult population. These include glomerulonephritis, polyarteritis nodosa and cryoglobulinemia. Other non-specific extrahepatic symptoms reported in adult studies include fatigue, renal impairment, lymphadenopathy, fever, and thyroid dysfunction[29-31].Although there appears to be a low incidence of extrahepatic manifestations in children, careful monitoring is still recommended.Indolfi *et al*[32] noted that subclinical thyroiditis (not autoimmune thyroid disease) has been reported in children with HCV. Other extrahepatic manifestations such as myopathy and opsoclonus-myoclonus syndrome have also been reported.

It is rare for HCV-associated liver disease to advance to the point of requiring liver transplant in children or adolescents. Based on retrospective analysis of the United Network of Organ Sharing, Gupta *et al*[33] found that children transplanted for HCV had a one-year survival of 97% and a three-year survival of 89% in the post-pediatric end-stage liver disease era. These findings are consistent with best practice liver transplant outcomes in children.

**Diagnosis and Screening Children and Adolescents**

In children older than 18 mo of age, diagnostic criteria are the same as those established for adults. An enzyme immunoassay is used to detect antibody (anti-HCV); however, the presence of anti-HCV alone is unable to distinguish if the patient has an active or resolved infection. Thus, in children with detectable anti-HCV antibodies, the next step is to verify viral infection by detecting HCV RNA. This is accomplished *via* polymerase chain reaction (PCR) testing. The diagnosis of chronic HCV infection is made based on presence of detectable HCV RNA for more than 6 mo[34,35].

The diagnosis of perinatal transmission in infants under 18 mo of age is confounded by the passive transfer of maternal antibodies, which can last for one year or more postnatally. Thus, anti-HCV testing is of limited value during the infantile period. Diagnosis in this age group can be reliably established by HCV RNA positivity on two or more occasions after two months of age[36-38].Criteria for spontaneous clearance requires two negative HCV RNA tests spread at least 6 mo apart, followed by negative anti-HCV testing after 18 mo of age[39,40].

For the population < 18 years of age, the screening guidelines are unclear. Assoumou *et al*[41] completed a cost effective analysis which revealed improved quality of life years (QALY) gained if universal screening for HCV was expanded to include adolescents (15 years and older). However, as the diagnosis of infants is more difficult to interpret, studies on the cost effectiveness of screening younger patients are needed. Recent efforts in the United States have focused on infants born to HCV infected mothers[42,43].

Jhaveri *et al*[44] endorsed a national strategy for HCV screening that integrates follow-up of infants with HCV exposure by using a model similar to HIV mother-to-child transmission prevention programs. This, and related calls to action to primary care providers, will lead to enhanced recognition and screening for children with HCV exposure, similar to the efforts to combat the HIV epidemic[45].

**Treatment**

The arrival of DAA therapies has led to a paradigm shift in the treatment and eradication of HCV in all populations[3,4]. The spate of DAAs available have been shown to be as safe and effective in children and adolescents as in the adult populations. Pegylated-interferon (PEG-IFN) and ribavirin (RBV), the initial recommended combination for treatment of HCV in children and adolescents, ae no longer recommended[46]. DAA therapies are specific and more effective at achieving sustained virologic response (SVR) in the pediatric population with few side effects. DAA therapies can also achieve SVR in no more than 12 wk of treatment, as compared to the RBV and PEG-IFN combination which required 48 wk of treatment, close monitoring, and significant side effect profiles including pancytopenia. Furthermore, regimens of PEG-IFN have sustained efficacy of only just above 50%, whereas DAA regimens have been shown to be persistently more effective (SVR > 95%) in children[3,4,17,46,47].

DAAs target three HCV proteins: (1) The nonstructural protein 3/4A (NS3/4A) protease inhibitors (PIs) which work by inhibiting HCV polyprotein processing; (2) NS5A inhibitors, which inhibit viral replication and assembly; and (3) NS5B polymerase inhibitors that block HCV RNA replication[48,49]. By combining two or more of these classes of drugs with different mechanisms attacking the Hepatitis C virus, DAAs are able achieve high SVR rates.

Over the past few years, several phase 2 clinical trials have been completed revealing the safety and efficacy of DAA therapy in children as young as 3 years of age (Table 1)[50-77]. For example, the first pediatric trial showed the safety and efficacy of Harvoni, the combination of Ledipasvir (90 mg) and sofosbuvir (400 mg), for treatment of HCV genotype 1 over a 12 wk period in children ages 12-17 years[50]. Subsequent clinical trials have been completed which show the efficacy and safety of newer combinations of DAA therapy for a wider range of HCV genotypes and pediatric age groups. For example, Jonas *et al*[74] reported the utility of the pangenotypic combination of glecaprevir (300 mg) and pibrentasvir (120 mg) in children ages 12-17 years. They found 100% SVR at 12 wk post therapy (SVR12) in as few as 8 wk of treatment. The safety profile was also consistent with that in adults. Wirth *et al*[75], reported that the fixed-dose combination of elbasvir/grazoprevir in children ages 3-17 years for HCV genotypes 1 and 4 was safe and efficacious in all study participants. Furthermore, SVR12 was achieved by all 57 participants. Sokal *et al*[76] also recently completed a study on the safety and tolerability of sofosbuvir/velpatasvir in pediatric patients aged 3–17 years with chronic HCV infection through 24-wk post-treatment. They found a 92% SVR12 rate regardless of HCV genotype, prior treatment experience, or presence of compensated cirrhosis.

Rosenthal *et al*[72] revealed that sofosbuvir plus ribavirin (RBV) was well-tolerated and highly effective in children aged 3 to < 12 years with chronic HCV genotype 2 or 3 infection. However, over one-third of the participants experienced gastrointestinal symptoms (vomiting, diarrhea), common side effects to RBV treatment. This combination is an option for young children until we have more published evidence for RBV-free DAA regimens. The hope is that by early 2021, we will have approval by the United States Food and Drug Administration (FDA) for the use of a wide variety of DAA combination therapies.

Higher risk groups, such as children who are survivors of cancer, have also had high success rates with DAA therapy. El-Shabrawi *et al*[66] prospectively followed 20 childhood cancer survivors ages 8-17 years with HCV genotype 4 in Egypt. They all received Sofosbuvir plus Daclatasvir over a 12 wk period. They found 100% SVR12 in their study group without any treatment related adverse events. Furthermore, no relapses were detected during treatment and throughout the follow up period (36 wk) for either the original malignant disease or the HCV infection.

Studies are also assessing the efficacy of smaller doses and shorter duration[60,67,77]. For example, Behairy *et al*[77] reported the effect of a shortened 8-wk regimen of ledipasvir/sofosbuvir at smaller dosing of 45 mg and 200 mg respectively. They found that this regimen is safe and effective with 100% SVR12 in treatment-naïve children aged 4-10 years with chronic HCV infection genotype 4.

**Where do we stand?**

The American Association for the Study of Liver Diseases (AASLD) recently published updated guidelines for the evaluation and management of HCV infection to reflect the DAA era[78]. The AASLD supports the use of ribavirin-free DAA regimens as early as possible (all children > 3 years of age) to avoid future complications. A policy paper from the North American Society of Pediatric Gastroenterology Hepatology and Nutrition (NASPGHAN), included pediatric guidelines for treating children with DAA therapy[79]. They agreed with starting applicable DAA therapy as early as 3 years of age.

Outside of North America, guidelines are being updated to reflect the advent of DAA therapy. The European Association for the Study of the Liver (EASL) recently published a new guidance for management of HCV[80]. They recommend treating HCV positive children (with or without cirrhosis) as young as 3 years of age with DAA regimens of either combined sofosbuvir and velpatasvir, or glecaprevir and pibrentasvir. Indolfi *et al*[46] as part of the European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) also updated their position to recommend initiation of DAA therapy for children as young as 3 years of age with HCV, regardless of the presence of fibrosis or active inflammation. Currently, we agree with AASLD, NASPGHAN, EASL, and ESPGHAN for an aggressive approach to treating children 3 years of age and older with a RBV-free DAA combination. Furthermore, we agree with these worldwide guidelines that if there is any signs or evidence of fibrosis, then patients should continue to be monitored even after completing DAA therapy and achieving SVR (please refer to monitoring below).

Anecdotally, one of the main hurdles is determining an age when a young child is capable of daily compliance with the medications for the recommended 8-12 wk period. The advent of DAA therapies in the form of granules/pellets is a promising strategy for younger children who cannot swallow whole tablets. For example, Schwarz *et al*[73] allowed for the granules to be sprinkled on a spoonful of nonacidic soft food, such as pudding or ice cream. SVR12 was achieved in 97% of patients, with only one patient discontinuing the trial after 5 d due to "abnormal drug taste".

Cost-effective analyses for treating children with DAA therapy are limited. Nguyen *et al*[81] found that early DAA treatment in adolescent patients with chronic HCV infection was cost-effective compared with deferred treatment, with approximately $27000 per QALY gained after 30 years. Greenaway *et al*[82] published data comparing treatment at age 6 years *vs* delaying treatment until age 18 years. In their model covering 20 years and treating 10000 children early, 330 cases of cirrhosis, 18 cases of hepatocellular carcinoma, and 48 Liver-related deaths would be avoided. The incremental cost-effectiveness ratio of early treatment compared to delayed treatment was approximately $12690 per QALY gained and considered cost-effective. Thus delaying treatment until age 18 years results in an increased lifetime risk of late stage liver complications that can otherwise be avoided. Early treatment is associated with saving money and lives, as well as improving quality of life.

**Improving the Cascade of Care**

In addition to inadequate screening, a major barrier to treatment and elimination is access to care and treatment. However, several programs have been conceived in order to provide DAA therapy to more individuals, with a focus in the primary care setting. In Australia, DAA treatments are available through the national Pharmaceutical Benefits Scheme (PBS) as of 2016. The PBS is a publicly funded scheme which provides highly subsidized prescription drugs *via* Australia’s universal healthcare system[83]. Australia was also one of the first countries to allow DAA treatment to be initiated by general practitioners. Since the advent of these practices, they have seen marked improvements in the cascade of hepatitis C care among patients attending primary care clinics[84].

In the United States, certain regions have much higher rates of HCV infection. For example, the Appalachian region leads the nation in reported new cases. Thus, new developmental strategies have been created focusing on these communities. The Kentucky Hepatitis Academic Mentorship Program (KHAMP) was created with the goal to build a hepatitis C elimination model which would then be easily modified and used to improve the health of rural and underserved communities throughout the Appalachian region. KHAMP has trained primary care providers on HCV epidemiology, diagnosis, management, treatment and prevention. General practitioners in this region are thus equipped with the skills needed to increase the number of individuals treated, ensuring that they will no longer be required to travel and consult with a specialist in order to prescribe DAA therapy[17,85,86].

This blueprint is being applied to the rest of the United States, continuing the focus on the Appalachian region. For example, West Virginia has recently implemented the West Virginia Hepatitis Academic Mentoring Partnership which will use the same strategies as KHAMP to provide education for primary care providers on HCV[86,87]. Virginia and Ohio are also participating to improve their education and access at the primary care level.

The advent of telemedicine has also had a positive impact towards treating HCV. Arora *et al*[88] developed the Extension for Community Healthcare Outcomes (ECHO) model. In a prospective cohort study, the ECHO model through use of video-conferencing technology, trained primary care providers to care for underserved populations with HCV infection who live in New Mexico. Results showed that ECHO was an effective approach to treating HCV infection in underserved communities. Piao *et al*[89] have implemented ECHO to California with improvements in SVR, advocating for such programs to be an essential part of HCV care moving forward.

In Australia, hepatitis C treatment (DAA therapy) using a decentralized, nurse-led telemedicine model of care has been highly effective at reaching a treating large numbers of prisoners, many of which are IV drug abusers[90]. Canada has also implemented a telemedicine program in order to effectively increase the use of DAA therapy with a high success rate of SVR (approximately 95%)[91]. As more programs are being initiated, the possibility of reaching the WHO goal of eradication by 2030 is still possible.

**Impact of Treatment on Progression**

Progression of HCV from an inflammatory hepatitis, to fibrosis, and eventually cirrhosis can occur starting in early childhood. In the past, most HCV-infected children would develop chronic HCV with a lifetime risk of liver disease. Modin *et al*[92] quantified the development of long-term liver disease and the effect of treatment in patients infected with HCV in childhood. They reported that liver disease developed in 32% of patients, a median of 33 years after infection; patients with perinatal exposure developed cirrhosis at an earlier age than the rest of the risk groups. The incidence of HCC was 5%, liver transplant 4% and death occurred in 3%. Among those treated there was a higher mortality rate among patients that did not achieve an SVR, and treatment was more effective in patients without cirrhosis. Disease progression was less frequent than in patients with cirrhosis at the time of therapy. The authors make a strong case for early treatment, before development of cirrhosis.

**Monitoring**

Finding non-invasive methods to assess for progression to fibrosis is an important aspect of monitoring children with chronic HCV. Transient elastography (TE) *via* ultrasound (US) evaluation of the liver is gaining traction in the pediatric population[93]. TE as a measurement of liver fibrosis has been validated in a variety of chronic liver diseases, including HCV[94-97].

Pokorska-Śpiewak *et al*[98] reported their prospective analysis on the prevalence of fibrosis in adolescents (12-17 years) with chronic HCV. Using TE, they found that over 10% of their patients had evidence of significant fibrosis (fibrosis score > 2), and that 9% had evidence of cirrhosis (Fibrosis score of 4). Other markers of liver fibrosis, such as the aspartate transaminase-to-platelet ratio index score, correlated positively with liver stiffness from TE.Otherwise, serial monitoring with in-clinic visits, as well as laboratory testing of aminotransferases and gamma-glutamyl transferase are recommended to occur at least twice yearly. Monitoring for signs of HCC with serum alpha-fetoprotein and US imaging is also warranted[29,99,100].

Based on the previously completed studies on DAA therapy in pediatrics, our current practice involves obtaining HCV PCR at baseline (prior to initiation of DAA therapy), at 4 wk, at 12 wk, and at 24 wk post initiation of therapy[50,54,70]. As long as there was no evidence of long-term damage (fibrosis, cirrhosis, *etc.*), then patients can have a repeat HCV PCR one year after completion of therapy to affirm SVR[50,54,72-76,81]. No pediatric studies with the children completing the DAA therapy has revealed evidence of children being unresponsive to DAA therapies.

Children with evidence of liver fibrosis should continue to be closely monitored even after eradication of their underlying HCV. However, adult studies are emerging which reveal that fibrosis may be to-some-extent reversed by DAA treatment[101-104]. One study revealed a 32% reduction in liver stiffness measurements after DAA completion among 392 adults with chronic HCV and fibrosis[105]. However, for patients with evidence of high-grade fibrosis or cirrhosis, they are still at high risk of developing HCC even after achieving SVR[106]. More histological data is needed to further support the hypothesis of improved liver scarring post DAA treatment. At this time, children with evidence of fibrosis must be closely followed given the continued risk of complications such as HCC and portal hypertension.

**Impact of DAA therapy on Liver Transplant**

The number of patients requiring HCV-related liver transplant has decreased, increasing organ availability for other liver disorders, such as NASH. In addition, given the safety and effectiveness of DAA therapy, the idea of placing HCV-infected livers into uninfected recipients is gaining traction. With the rising demand of liver transplant, treating recipients with an appropriate course of DAA therapy immediately after transplant appears safe and efficacious[107,108]. In one small study, 8 veterans received HCV-infected livers and all 8 became viremic with HCV. However, after a 12 wk course of DAA treatment, all 8 patients achieved SVR12[109]. Bohorquez *et al*[110] increased this sample size and, after completing an appropriate DAA regimen, had 100% SVR12 in all 51 HCV-naïve patients who received HCV positive livers. Therefore, solid organ transplant from HCV infected recipients appears to be safe, is associated with excellent outcomes, and should be considered for recipients who would benefit from receiving an organ earlier than they would if they waited for an organ from an uninfected donor. Thus, reducing wait-list associated mortality. The same concept applies to other solid organ transplants. While no studies has been performed, based on the efficacy of DAA therapy in children, using HCV-infected donors should be an option.

**CoronaVirus Disease and HCV**

The coronavirus disease 2019 (COVID-19) pandemic has significantly impacted access and healthcare practices for many patients and providers, including the pediatric population. As children will now have access to DAA therapies and potential HCV cure, it is imperative that diagnosis and treatment of this population is not overlooked. A related issue is for patients with chronic liver disease to avoid COVID-19 exposure and infection, by educating patients/parents on the risk and the recommended precautions[111]. This is especially true in rare cases of children with cirrhosis or end-stage liver disease secondary to HCV, as there appears to be a higher risk of a severe course of COVID-19[112].

The advent of telemedicine is playing an important role in the care of children with HCV. This allows patients to undergo lab testing locally, for DAA prescriptions to be sent to their home, and allow providers to safely communicate, educate, and closely monitor their patients during treatment[113]. Thus this pandemic should not be a hindrance to continuing the goal of eradication of HCV in the pediatric population.

**CONCLUSION**

The discovery of the HCV and the related advances in biomedical research-the establishment and implementation of diagnostic tests to ensure the safety of blood products, and antiviral drug development has, and will continue to have, a major impact on health care outcomes for patients of all ages…including the smallest victims. Enhanced screening and awareness efforts and continued education of healthcare providers will improve the outcomes of HCV infection in the pediatric population.

**REFERENCES**

1 **The Nobel Prize. The Nobel Prize in Physiology or Medicine 2020.** Nobel Media AB, 2020. [cited 21 October 2020]. Available from: https://www.nobelprize.org/prizes/medicine/2020/summary/

2 **Callaway E**, Ledford H. Virologists who discovered hepatitis C win medicine Nobel. *Nature* 2020; **586**: 348 [PMID: 33020621 DOI: 10.1038/d41586-020-02763-x]

3 **Basyte-Bacevice V**, Kupcinskas J. Evolution and Revolution of Hepatitis C Management: From Non-A, Non-B Hepatitis Toward Global Elimination. *Dig Dis* 2020: 1-6 [PMID: 31905358 DOI: 10.1159/000505434]

4 **Spearman CW**, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. *Lancet* 2019; **394**: 1451-1466 [PMID: 31631857 DOI: 10.1016/S0140-6736(19)32320-7]

5 **Kim NG**, Kullar R, Khalil H, Saab S. Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics. *J Viral Hepat* 2020; **27**: 762-769 [PMID: 32386099 DOI: 10.1111/jvh.13317]

6 **Squires JE**, Balistreri WF. Hepatitis C virus infection in children and adolescents. *Hepatol Commun* 2017; **1**: 87-98 [PMID: 29404447 DOI: 10.1002/hep4.1028]

7 **Schmelzer J**, Dugan E, Blach S, Coleman S, Cai Z, DePaola M, Estes C, Gamkrelidze I, Jerabek K, Ma S, Montoya S, Razavi-Shearer D, Razavi-Shearer K, Robbins-Scott S, Razavi H, El Sayed MH. Global prevalence of hepatitis C virus in children in 2018: a modelling study. *Lancet Gastroenterol Hepatol* 2020; **5**: 374-392 [PMID: 31954439 DOI: 10.1016/S2468-1253(19)30385-1]

8 **Epstein RL**, Sabharwal V, Wachman EM, Saia KA, Vellozzi C, Hariri S, Linas BP. Perinatal Transmission of Hepatitis C Virus: Defining the Cascade of Care. *J Pediatr* 2018; **203**: 34-40.e1 [PMID: 30170857 DOI: 10.1016/j.jpeds.2018.07.006]

9 **Chou R**, Dana T, Fu R, Zakher B, Wagner J, Ramirez S, Grusing S, Jou JH. Screening for Hepatitis C Virus Infection in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA* 2020; Epub ahead of print [PMID: 32119034 DOI: 10.1001/jama.2019.20788]

10 **Evon DM**, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, Reeve BB, Serper M, Reau N, Rajender Reddy K, Di Bisceglie AM, Nelson DR, Golin CE, Lim JK, Fried MW. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. *J Hepatol* 2019; **71**: 486-497 [PMID: 31096006 DOI: 10.1016/j.jhep.2019.04.016]

11 **Dal Molin G**, D'Agaro P, Ansaldi F, Ciana G, Fertz C, Alberico S, Campello C. Mother-to-infant transmission of hepatitis C virus: rate of infection and assessment of viral load and IgM anti-HCV as risk factors. *J Med Virol* 2002; **67**: 137-142 [PMID: 11992574 DOI: 10.1002/jmv.2202]

12 **Resti M**, Azzari C, Mannelli F, Moriondo M, Novembre E, de Martino M, Vierucci A. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. *BMJ* 1998; **317**: 437-441 [PMID: 9703524 DOI: 10.1136/bmj.317.7156.437]

13 **Saez A**, Losa M, Lo Iacono O, Lozano C, Alvarez E, Pita L, Garcia-Monzón C. Diagnostic and prognostic value of virologic tests in vertical transmission of hepatitis C virus infection: results of a large prospective study in pregnant women. *Hepatogastroenterology* 2004; **51**: 1104-1108 [PMID: 15239255]

14 **Yeung LT**, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. *Hepatology* 2001; **34**: 223-229 [PMID: 11481604 DOI: 10.1053/jhep.2001.25885]

15 **Ruiz-Extremera A**, Salmerón J, Torres C, De Rueda PM, Giménez F, Robles C, Miranda MT. Follow-up of transmission of hepatitis C to babies of human immunodeficiency virus-negative women: the role of breast-feeding in transmission. *Pediatr Infect Dis J* 2000; **19**: 511-516 [PMID: 10877164 DOI: 10.1097/00006454-200006000-00004]

16 **Lopata SM**, McNeer E, Dudley JA, Wester C, Cooper WO, Carlucci JG, Espinosa CM, Dupont W, Patrick SW. Hepatitis C Testing Among Perinatally Exposed Infants. *Pediatrics* 2020; **145** [PMID: 32060140 DOI: 10.1542/peds.2019-2482]

17 **Squires JE**, Balistreri WF. Treatment of Hepatitis C: A New Paradigm toward Viral Eradication. *J Pediatr* 2020; **221**: 12-22.e1 [PMID: 32446469 DOI: 10.1016/j.jpeds.2020.02.082]

18 **Protopapas S**, Murrison LB, Wexelblatt SL, Blackard JT, Hall ES. Addressing the Disease Burden of Vertically Acquired Hepatitis C Virus Infection Among Opioid-Exposed Infants. *Open Forum Infect Dis* 2019; **6**: ofz448 [PMID: 32128320 DOI: 10.1093/ofid/ofz448]

19 **Epstein RL**, Wang J, Hagan L, Mayer KH, Puro J, Linas BP, Assoumou SA. Hepatitis C Virus Antibody Testing Among 13- to 21-Year-Olds in a Large Sample of US Federally Qualified Health Centers. *JAMA* 2019; **322**: 2245-2248 [PMID: 31821424 DOI: 10.1001/jama.2019.16196]

20 **Barritt AS 4th**, Lee B, Runge T, Schmidt M, Jhaveri R. Increasing Prevalence of Hepatitis C among Hospitalized Children Is Associated with an Increase in Substance Abuse. *J Pediatr* 2018; **192**: 159-164 [PMID: 29106926 DOI: 10.1016/j.jpeds.2017.09.016]

21 **Yeung LT**, To T, King SM, Roberts EA. Spontaneous clearance of childhood hepatitis C virus infection. *J Viral Hepat* 2007; **14**: 797-805 [PMID: 17927616 DOI: 10.1111/j.1365-2893.2007.00873.x]

22 **Indolfi G**, Mangone G, Bartolini E, Moriondo M, Azzari C, Resti M. Hepatitis C viraemia after apparent spontaneous clearance in a vertically infected child. *Lancet* 2016; **387**: 1967-1968 [PMID: 27203660 DOI: 10.1016/S0140-6736(16)00085-4]

23 **Bortolotti F**, Verucchi G, Cammà C, Cabibbo G, Zancan L, Indolfi G, Giacchino R, Marcellini M, Marazzi MG, Barbera C, Maggiore G, Vajro P, Bartolacci S, Balli F, Maccabruni A, Guido M; Italian Observatory for HCV Infection and Hepatitis C in Children. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. *Gastroenterology* 2008; **134**: 1900-1907 [PMID: 18439604 DOI: 10.1053/j.gastro.2008.02.082]

24 **Kelly D**, Sharif K, Brown RM, Morland B. Hepatocellular carcinoma in children. *Clin Liver Dis* 2015; **19**: 433-447 [PMID: 25921672 DOI: 10.1016/j.cld.2015.01.010]

25 **Younossi ZM**, Stepanova M, Schwarz KB, Wirth S, Rosenthal P, Gonzalez-Peralta R, Murray K, Henry L, Hunt S. Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin. *J Viral Hepat* 2018; **25**: 354-362 [PMID: 29193603 DOI: 10.1111/jvh.12830]

26 **Abu Faddan NH**, Shehata GA, Abd Elhafeez HA, Mohamed AO, Hassan HS, Abd El Sameea F. Cognitive function and endogenous cytokine levels in children with chronic hepatitis C. *J Viral Hepat* 2015; **22**: 665-670 [PMID: 25496114 DOI: 10.1111/jvh.12373]

27 **Santantonio T**, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Gentile A, Leandro G, Pastore G. Natural course of acute hepatitis C: a long-term prospective study. *Dig Liver Dis* 2003; **35**: 104-113 [PMID: 12747629 DOI: 10.1016/s1590-8658(03)00007-0]

28 **El-Guindi MA**. Hepatitis C Viral Infection in Children: Updated Review. *Pediatr Gastroenterol Hepatol Nutr* 2016; **19**: 83-95 [PMID: 27437184 DOI: 10.5223/pghn.2016.19.2.83]

29 **Cheng Z**, Zhou B, Shi X, Zhang Y, Zhang L, Chen L, Liu X. Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China. *Chin Med J (Engl)* 2014; **127**: 1206-1210 [PMID: 24709167]

30 **Sanzone AM**, Bégué RE. Hepatitis C and arthritis: an update. *Infect Dis Clin North Am* 2006; **20**: 877-889, vii [PMID: 17118294 DOI: 10.1016/j.idc.2006.09.010]

31 **Amarapurkar DN**, Amarapurkar AD. Extrahepatic manifestations of viral hepatitis. *Ann Hepatol* 2002; **1**: 192-195 [PMID: 15280806]

32 **Indolfi G**, Bartolini E, Olivito B, Azzari C, Resti M. Autoimmunity and extrahepatic manifestations in treatment-naïve children with chronic hepatitis C virus infection. *Clin Dev Immunol* 2012; **2012**: 785627 [PMID: 22645623 DOI: 10.1155/2012/785627]

33 **Gupta M**, Bahirwani R, Levine MH, Malik S, Goldberg D, Reddy KR, Shaked A. Outcomes in pediatric hepatitis C transplant recipients: analysis of the UNOS database. *Pediatr Transplant* 2015; **19**: 153-163 [PMID: 25495572 DOI: 10.1111/petr.12408]

34 **Mohan N**, González-Peralta RP, Fujisawa T, Chang MH, Heller S, Jara P, Kelly D, Mieli-Vergani G, Shah U, Murray KF. Chronic hepatitis C virus infection in children. *J Pediatr Gastroenterol Nutr* 2010; **50**: 123-131 [PMID: 20038846 DOI: 10.1097/MPG.0b013e3181c61995]

35 **Mack CL**, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, Rosenthal P, Schwarz KB; North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents. *J Pediatr Gastroenterol Nutr* 2012; **54**: 838-855 [PMID: 22487950 DOI: 10.1097/MPG.0b013e318258328d]

36 **Davison SM**, Mieli-Vergani G, Sira J, Kelly DA. Perinatal hepatitis C virus infection: diagnosis and management. *Arch Dis Child* 2006; **91**: 781-785 [PMID: 16923861 DOI: 10.1136/adc.2005.081877]

37 **Gibb DM**, Goodall RL, Dunn DT, Healy M, Neave P, Cafferkey M, Butler K. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. *Lancet* 2000; **356**: 904-907 [PMID: 11036896 DOI: 10.1016/s0140-6736(00)02681-7]

38 **Dunn DT**, Gibb DM, Healy M, Goodall RL, Butler K, Cafferkey M, Neave P. Timing and interpretation of tests for diagnosing perinatally acquired hepatitis C virus infection. *Pediatr Infect Dis J* 2001; **20**: 715-716 [PMID: 11465848 DOI: 10.1097/00006454-200107000-00016]

39 **Rerksuppaphol S**, Hardikar W, Dore GJ. Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. *J Gastroenterol Hepatol* 2004; **19**: 1357-1362 [PMID: 15610308 DOI: 10.1111/j.1440-1746.2004.03463.x]

40 **Jara P**, Resti M, Hierro L, Giacchino R, Barbera C, Zancan L, Crivellaro C, Sokal E, Azzari C, Guido M, Bortolotti F. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. *Clin Infect Dis* 2003; **36**: 275-280 [PMID: 12539067 DOI: 10.1086/345908]

41 **Assoumou SA**, Tasillo A, Leff JA, Schackman BR, Drainoni ML, Horsburgh CR, Barry MA, Regis C, Kim AY, Marshall A, Saxena S, Smith PC, Linas BP. Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings. *Clin Infect Dis* 2018; **66**: 376-384 [PMID: 29020317 DOI: 10.1093/cid/cix798]

42 **Chappell CA**, Hillier SL, Crowe D, Meyn LA, Bogen DL, Krans EE. Hepatitis C Virus Screening Among Children Exposed During Pregnancy. *Pediatrics* 2018; **141** [PMID: 29720535 DOI: 10.1542/peds.2017-3273]

43 **Kuncio DE**, Newbern EC, Johnson CC, Viner KM. Failure to Test and Identify Perinatally Infected Children Born to Hepatitis C Virus-Infected Women. *Clin Infect Dis* 2016; **62**: 980-985 [PMID: 26797211 DOI: 10.1093/cid/ciw026]

44 **Jhaveri R**. We Need a New National Strategy for Hepatitis C Virus Screening. *Pediatrics* 2020; **145** [PMID: 32060139 DOI: 10.1542/peds.2019-3060]

45 **Nesheim SR**, FitzHarris LF, Mahle Gray K, Lampe MA. Epidemiology of Perinatal HIV Transmission in the United States in the Era of Its Elimination. *Pediatr Infect Dis J* 2019; **38**: 611-616 [PMID: 30724833 DOI: 10.1097/INF.0000000000002290]

46 **Indolfi G**, Hierro L, Dezsofi A, Jahnel J, Debray D, Hadzic N, Czubkowski P, Gupte G, Mozer-Glassberg Y, van der Woerd W, Smets F, Verkade HJ, Fischler B. Treatment of Chronic Hepatitis C Virus Infection in Children: A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. *J Pediatr Gastroenterol Nutr* 2018; **66**: 505-515 [PMID: 29287014 DOI: 10.1097/MPG.0000000000001872]

47 **Druyts E**, Thorlund K, Wu P, Kanters S, Yaya S, Cooper CL, Mills EJ. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. *Clin Infect Dis* 2013; **56**: 961-967 [PMID: 23243171 DOI: 10.1093/cid/cis1031]

48 **Zeng H**, Li L, Hou Z, Zhang Y, Tang Z, Liu S. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. *Int J Med Sci* 2020; **17**: 892-902 [PMID: 32308542 DOI: 10.7150/ijms.43079]

49 **Sullivan JC**, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, Adda N, Martin EC, Beumont M, Jacobson IM, Sherman KE, Zeuzem S, Picchio G, Kieffer TL. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. *Clin Infect Dis* 2013; **57**: 221-229 [PMID: 23575197 DOI: 10.1093/cid/cit226]

50 **Balistreri WF**, Murray KF, Rosenthal P, Bansal S, Lin CH, Kersey K, Massetto B, Zhu Y, Kanwar B, German P, Svarovskaia E, Brainard DM, Wen J, Gonzalez-Peralta RP, Jonas MM, Schwarz K. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. *Hepatology* 2017; **66**: 371-378 [PMID: 27997679 DOI: 10.1002/hep.28995]

51 **Wirth S**, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, Balistreri WF, Lin CH, Hardikar W, Kersey K, Massetto B, Kanwar B, Brainard DM, Shao J, Svarovskaia E, Kirby B, Arnon R, Murray KF, Schwarz KB. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. *Hepatology* 2017; **66**: 1102-1110 [PMID: 28543053 DOI: 10.1002/hep.29278]

52 **Hashmi MA**, Cheema HA. Effectiveness and Safety of Sofosbuvir in Treatment-NäiveChildren with Hepatitis C Infection. *J Coll Physicians Surg Pak* 2017; **27**: 423-426 [PMID: 28818165]

53 **El-Khayat HR**, Kamal EM, El-Sayed MH, El-Shabrawi M, Ayoub H, RizK A, Maher M, El Sheemy RY, Fouad YM, Attia D. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. *Aliment Pharmacol Ther* 2018; **47**: 838-844 [PMID: 29349793 DOI: 10.1111/apt.14502]

54 **Murray KF**, Balistreri WF, Bansal S, Whitworth S, Evans HM, Gonzalez-Peralta RP, Wen J, Massetto B, Kersey K, Shao J, Garrison KL, Parhy B, Brainard DM, Arnon R, Gillis LA, Jonas MM, Lin CH, Narkewicz MR, Schwarz K, Rosenthal P. Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11. *Hepatology* 2018; **68**: 2158-2166 [PMID: 30070726 DOI: 10.1002/hep.30123]

55 **El-Karaksy H**, Mogahed EA, Abdullatif H, Ghobrial C, El-Raziky MS, El-Koofy N, El-Shabrawi M, Ghita H, Baroudy S, Okasha S. Sustained Viral Response in Genotype 4 Chronic Hepatitis C Virus-infected Children and Adolescents Treated With Sofosbuvir/Ledipasvir. *J Pediatr Gastroenterol Nutr* 2018; **67**: 626-630 [PMID: 30216203 DOI: 10.1097/MPG.0000000000002101]

56 **Leung DH**, Wirth S, Yao BB, Viani RM, Gonzalez-Peralta RP, Jonas MM, Lobritto SJ, Narkewicz MR, Sokal E, Fortuny C, Hsu EK, Del Valle-Segarra A, Zha J, Larsen L, Liu L, Shuster DL, Cohen DE, Rosenthal P. Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4. *Hepatol Commun* 2018; **2**: 1311-1319 [PMID: 30411078 DOI: 10.1002/hep4.1250]

57 **Alkaaby BA**, Al-Ethawi AE. The effectiveness of oral antiviral (Sofosbuvir/Ledipasvir) in treating children with HCV infection. *Pak J Med Sci* 2018; **34**: 1353-1356 [PMID: 30559784 DOI: 10.12669/pjms.346.15722]

58 **Tucci F**, Calbi V, Barzaghi F, Migliavacca M, Ferrua F, Bernardo ME, Canarutto D, Consiglieri G, Recupero S, Calzatini F, Gabaldo M, Lucano C, Casiraghi M, Darin S, Dionisio F, Marktel S, Cestone E, Finazzi R, Mieli-Vergani G, Boeri E, Appleby J, Abd Elaziz D, Ciceri F, Aiuti A, Cicalese MP. Successful Treatment With Ledipasvir/Sofosbuvir in an Infant With Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency With HCV Allowed Gene Therapy with Strimvelis. *Hepatology* 2018; **68**: 2434-2437 [PMID: 30014500 DOI: 10.1002/hep.30160]

59 **El-Shabrawi MHF**, Kamal NM, El-Khayat HR, Kamal EM, AbdElgawad MMAH, Yakoot M. A pilot single arm observational study of sofosbuvir/ledipasvir (200 + 45 mg) in 6- to 12- year old children. *Aliment Pharmacol Ther* 2018; **47**: 1699-1704 [PMID: 29696674 DOI: 10.1111/apt.14677]

60 **El-Shabrawi MH**, Abdo AM, El-Khayat HR, Yakoot M. Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, With Chronic Hepatitis C Infection. *J Pediatr Gastroenterol Nutr* 2018; **66**: 425-427 [PMID: 29135824 DOI: 10.1097/MPG.0000000000001838]

61 **Yakoot M**, El-Shabrawi MH, AbdElgawad MM, Mahfouz AA, Helmy S, Abdo AM, El-Khayat HR. Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients With Chronic Hepatitis C Infection. *J Pediatr Gastroenterol Nutr* 2018; **67**: 86-89 [PMID: 29570560 DOI: 10.1097/MPG.0000000000001968]

62 **Quintero J**, Juampérez J, Julio E, Cabello V, Mercadal-Hally M, Soler-Palacín P, Segarra Ó, Rodrigo C. [Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents]. *An Pediatr (Barc)* 2019; **90**: 141-147 [PMID: 30126773 DOI: 10.1016/j.anpedi.2018.07.007]

63 **Abdel Ghaffar TY**, El Naghi S, Abdel Gawad M, Helmy S, Abdel Ghaffar A, Yousef M, Moafy M. Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4. *J Viral Hepat* 2019; **26**: 263-270 [PMID: 30380158 DOI: 10.1111/jvh.13032]

64 **Fouad HM**, Ahmed Mohamed A, Sabry M, Abdel Aziz H, Eysa B, Rabea M. The Effectiveness of Ledipasvir/Sofosbuvir in Youth With Genotype 4 Hepatitis C Virus: A Single Egyptian Center Study. *Pediatr Infect Dis J* 2019; **38**: 22-25 [PMID: 30234791 DOI: 10.1097/INF.0000000000002189]

65 **Ohya K**, Kawaoka T, Imamura M, Morio K, Nakahara T, Murakami E, Yamauchi M, Hiramatsu A, Tsuge M, Aikata H, Chayama K. Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection. *Intern Med* 2020; **59**: 941-944 [PMID: 31813916 DOI: 10.2169/internalmedicine.3824-19]

66 **El-Shabrawi MH**, Sherief LM, Yakoot M, Kamal NM, Almalky MA, AbdElgawad MM, Mahfouz AA, Helmy S, Kamal EM, Attia D, El-Khayat HR. Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy. *World J Clin Cases* 2019; **7**: 2247-2255 [PMID: 31531319 DOI: 10.12998/wjcc.v7.i16.2247]

67 **Serranti D**, Dodi I, Nicastro E, Cangelosi AM, Riva S, Ricci S, Bartolini E, Trapani S, Mastrangelo G, Vajro P, D'Antiga L, Resti M, Indolfi G. Shortened 8-Week Course of Sofosbuvir/Ledipasvir Therapy in Adolescents With Chronic Hepatitis C Infection. *J Pediatr Gastroenterol Nutr* 2019; **69**: 595-598 [PMID: 31335836 DOI: 10.1097/MPG.0000000000002449]

68 **Marascio N**, Mazzitelli M, Pavia G, Giancotti A, Barreca GS, Costa C, Pisani V, Greco G, Serapide F, Trecarichi EM, Casalinuovo F, Liberto MC, Matera G, Torti C. Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4. *Cells* 2019; **8** [PMID: 31060315 DOI: 10.3390/cells8050416]

69 **Fouad HM**, Sabry MA, Ahmed A, Hassany M, Al Soda MF, Abdel Aziz H. Generic Ledipasvir-Sofosbuvir Treatment for Adolescents With Chronic Hepatitis C Virus Infection. *J Pediatric Infect Dis Soc* 2020; **9**: 386-389 [PMID: 31310312 DOI: 10.1093/jpids/piz041]

70 **Kamal EM**, El-Shabrawi M, El-Khayat H, Yakoot M, Sameh Y, Fouad Y, Attia D. Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3-6 years of age. *Liver Int* 2020; **40**: 319-323 [PMID: 31758735 DOI: 10.1111/liv.14308]

71 **El-Araby HA**, Behairy BE, El-Guindi MA, Adawy NM, Allam AA, Sira AM, Khedr MA, Elhenawy IA, Sobhy GA, Basiouny HEDM, Salem ME, Abdel-Aziz SA, Fouad OA, Ayoub BA. Generic sofosbuvir/ledipasvir for the treatment of genotype 4 chronic hepatitis C in Egyptian children (9-12 years) and adolescents. *Hepatol Int* 2019; **13**: 706-714 [PMID: 31515739 DOI: 10.1007/s12072-019-09985-w]

72 **Rosenthal P**, Schwarz KB, Gonzalez-Peralta RP, Lin CH, Kelly DA, Nightingale S, Balistreri WF, Bansal S, Jonas MM, Massetto B, Brainard DM, Hsueh CH, Shao J, Parhy B, Davison S, Feiterna-Sperling C, Gillis LA, Indolfi G, Sokal EM, Murray KF, Wirth S. Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection. *Hepatology* 2020; **71**: 31-43 [PMID: 31222783 DOI: 10.1002/hep.30821]

73 **Schwarz KB**, Rosenthal P, Murray KF, Honegger JR, Hardikar W, Hague R, Mittal N, Massetto B, Brainard DM, Hsueh CH, Shao J, Parhy B, Narkewicz MR, Rao GS, Whitworth S, Bansal S, Balistreri WF. Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C. *Hepatology* 2020; **71**: 422-430 [PMID: 31220349 DOI: 10.1002/hep.30830]

74 **Jonas MM**, Squires RH, Rhee SM, Lin CW, Bessho K, Feiterna-Sperling C, Hierro L, Kelly D, Ling SC, Strokova T, Del Valle-Segarra A, Lovell S, Liu W, Ng TI, Porcalla A, Gonzalez YS, Burroughs M, Sokal E. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study. *Hepatology* 2020; **71**: 456-462 [PMID: 31254392 DOI: 10.1002/hep.30840]

75 **Wirth S**, Gonzalez-Peralt R, Squires R, Mutschler F, Lang T, Pawlowska M, Sluzewski W, Majda-Stanislawska E, Fischler B, Balistreri WF, Jonas MM, Blondet N, Rosenthal P, Alkhouri N, Romero R, Grandhi A, Castronuovo P, Caro L, Rosenbloom D, Du L, Harber BA. Elbasvir/Grazoprevir in Children Aged 3 to <18 Years With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: Final Results From an Iterative Pharmacokinetic Modeling Study. Poster session presented at: the American Association for the Study of Liver Diseases (AASLD) Liver Meeting Digital Experience™ 2020; 2020 November 13-16

76 **Sokal E**, Schwarz K, Rosenthal P, Verucchi G, Lin C, Balistreri WF, Wen J, Whitworth S, Leung D, Bansal S, Karnsakul W, Mangia A, Rao GS, Shao J, Hsueh CH, Parhy B, Gaggar A, Kersey K, Narkewicz MR, Gonzalez-Peralta RP, Murray KF, Romero R, Jonas MM. Safety and Efficacy of Sofosbuvir/Velpatasvir for the Treatment of Chronic Hepatitis C Infection in Adolescents and Children Aged 3 to 17 Years Old Through 24 Weeks Posttreatment. Poster session presented at: the American Association for the Study of Liver Diseases (AASLD) Liver Meeting Digital Experience™ 2020; 2020 November 13-16

77 **Behairy BE**, El-Araby HA, El-Guindi MA, Basiouny HM, Fouad OA, Ayoub BA, Marei AM, Sira MM. Safety and Efficacy of 8 Weeks Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10 Years. *J Pediatr* 2020; **219**: 106-110 [PMID: 32008767 DOI: 10.1016/j.jpeds.2019.12.034]

78 **Ghany MG**, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. *Hepatology* 2020; **71**: 686-721 [PMID: 31816111 DOI: 10.1002/hep.31060]

79 **Leung DH**, Squires JE, Jhaveri R, Kerkar N, Lin CH, Mohan P, Murray KF, Gonzalez-Peralta RP, Roberts EA, Sundaram SS. Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper. *J Pediatr Gastroenterol Nutr* 2020; **71**: 407-417 [PMID: 32826718 DOI: 10.1097/MPG.0000000000002814]

80 **European Association for the Study of the Liver**; Clinical Practice Guidelines Panel: Chair:; EASL Governing Board representative:; Panel members:. EASL recommendations on treatment of hepatitis C: Final update of the series☆. *J Hepatol* 2020; **73**: 1170-1218 [PMID: 32956768 DOI: 10.1016/j.jhep.2020.08.018]

81 **Nguyen J**, Barritt AS 4th, Jhaveri R. Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection. *J Pediatr* 2019; **207**: 90-96 [PMID: 30738661 DOI: 10.1016/j.jpeds.2018.12.012]

82 **Greenaway E**, Haines A, Ling SC, Krahn M. Treatment of Chronic Hepatitis C in Young Children Reduces Adverse Outcomes and Is Cost-Effective Compared to Deferring Treatment to Adulthood. *J Pediatr* 2020 [PMID: 32890583 DOI: 10.1016/j.jpeds.2020.08.088]

83 **November 2016 Positive Recommendations.** Canberra, Australia: Pharmaceutical Benefits Advisory Committee, 2016

84 **Traeger MW**, Pedrana AE, van Santen DK, Doyle JS, Howell J, Thompson AJ, El-Hayek C, Asselin J, Polkinghorne V, Membrey D, Bramwell F, Carter A, Guy R, Stoové MA, Hellard ME; EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood-borne Viruses and Sexually Transmitted Infections (ACCESS). The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services. *PLoS One* 2020; **15**: e0235445 [PMID: 32603349 DOI: 10.1371/journal.pone.0235445]

85 **Kentucky Rural Health Association**. Kentucky Hepatitis Academic Mentorship Program, 2020. [cited 21 October 2020]. Available from: https://kyrha.org/resources/Documents/Edit%202019%20KHAMP%20Agenda%20and%20objectives.pdf

86 **Cave B**, Sanders K, Moser S, Brawley R, McCormick T, Espinosa C. Working Toward Elimination of Hepatitis C: The Kentucky Hepatitis Academic Mentorship Program. *Clin Liver Dis (Hoboken)* 2020; **16**: 123-126 [PMID: 33005394 DOI: 10.1002/cld.1028]

87 **West Virginia Hepatitis Academic Mentoring Partnership**. Mission and Action Plan. [cited 21 October 2020]. Available from: https://wvrha.org/mission-action-plan/

88 **Arora S**, Thornton K, Murata G, Deming P, Kalishman S, Dion D, Parish B, Burke T, Pak W, Dunkelberg J, Kistin M, Brown J, Jenkusky S, Komaromy M, Qualls C. Outcomes of treatment for hepatitis C virus infection by primary care providers. *N Engl J Med* 2011; **364**: 2199-2207 [PMID: 21631316 DOI: 10.1056/NEJMoa1009370]

89 **Piao C**, Terrault NA, Sarkar S. Telemedicine: An Evolving Field in Hepatology. *Hepatol Commun* 2019; **3**: 716-721 [PMID: 31061958 DOI: 10.1002/hep4.1340]

90 **Papaluca T**, McDonald L, Craigie A, Gibson A, Desmond P, Wong D, Winter R, Scott N, Howell J, Doyle J, Pedrana A, Lloyd A, Stoove M, Hellard M, Iser D, Thompson A. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care. *J Hepatol* 2019; **70**: 839-846 [PMID: 30654067 DOI: 10.1016/j.jhep.2019.01.012]

91 **Cooper CL**, Hatashita H, Corsi DJ, Parmar P, Corrin R, Garber G. Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients. *Ann Hepatol* 2017; **16**: 874-880 [PMID: 29055923 DOI: 10.5604/01.3001.0010.5277]

92 **Modin L**, Arshad A, Wilkes B, Benselin J, Lloyd C, Irving WL, Kelly DA. Epidemiology and natural history of hepatitis C virus infection among children and young people. *J Hepatol* 2019; **70**: 371-378 [PMID: 30496763 DOI: 10.1016/j.jhep.2018.11.013]

93 **Fang C**, Sidhu PS. Ultrasound-based liver elastography: current results and future perspectives. *Abdom Radiol (NY)* 2020; **45**: 3463-3472 [PMID: 32918106 DOI: 10.1007/s00261-020-02717-x]

94 **Alem SA**, Abdellatif Z, Mabrouk M, Zayed N, Elsharkawy A, Khairy M, Musa S, Anwar I, Yosry A. Diagnostic accuracy of acoustic radiation force impulse elastography (ARFI) in comparison to other non-invasive modalities in staging of liver fibrosis in chronic HCV patients: single-center experience. *Abdom Radiol (NY)* 2019; **44**: 2751-2758 [PMID: 31028432 DOI: 10.1007/s00261-019-02031-1]

95 **Højte C**, Jørgensen MH, Jensen F, Katzenstein TL, Skov M. Extended Screening for Cystic Fibrosis-related Liver Disease Including Elastography in Children and Adolescents. *J Pediatr Gastroenterol Nutr* 2020; **71**: 663-668 [PMID: 33093375 DOI: 10.1097/MPG.0000000000002872]

96 **Tada T**, Nishimura T, Yoshida M, Iijima H. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography. *J Med Ultrason (2001)* 2020; **47**: 511-520 [PMID: 33089412 DOI: 10.1007/s10396-020-01058-y]

97 **Ren X**, Zhang L, Xia S, Chen Z, Zhou W, Ji R, Zhou J, Lin Y, Zhan W. A New Visual Transient Elastography Technique for Grading Liver Fibrosis in Patients With Chronic Hepatitis B. *Ultrasound Q* 2020 [PMID: 32976320 DOI: 10.1097/RUQ.0000000000000509]

98 **Pokorska-Śpiewak M**, Dobrzeniecka A, Lipińska M, Tomasik A, Aniszewska M, Marczyńska M. Liver Fibrosis Evaluated With Transient Elastography in 35 Children With Chronic Hepatitis C Virus Infection. *Pediatr Infect Dis J* 2021; **40**: 103-108 [PMID: 33021594 DOI: 10.1097/INF.0000000000002913]

99 **El-Shabrawi MH**, Kamal NM. Burden of pediatric hepatitis C. *World J Gastroenterol* 2013; **19**: 7880-7888 [PMID: 24307782 DOI: 10.3748/wjg.v19.i44.7880]

100 **Pawlowska M**, Sobolewska-Pilarczyk M, Domagalski K. Hepatitis C virus infection in children in the era of direct-acting antiviral. *World J Gastroenterol* 2018; **24**: 2555-2566 [PMID: 29962813 DOI: 10.3748/wjg.v24.i24.2555]

101 **Ioannou GN**, Feld JJ. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection? *Gastroenterology* 2019; **156**: 446-460.e2 [PMID: 30367836 DOI: 10.1053/j.gastro.2018.10.033]

102 **Chen SH**, Lai HC, Chiang IP, Su WP, Lin CH, Kao JT, Chuang PH, Hsu WF, Wang HW, Chen HY, Huang GT, Peng CY. Changes in liver stiffness measurement using acoustic radiation force impulse elastography after antiviral therapy in patients with chronic hepatitis C. *PLoS One* 2018; **13**: e0190455 [PMID: 29293628 DOI: 10.1371/journal.pone.0190455]

103 **Rockey DC**. Fibrosis reversal after hepatitis C virus elimination. *Curr Opin Gastroenterol* 2019; **35**: 137-144 [PMID: 30865043 DOI: 10.1097/MOG.0000000000000524]

104 **Knop V**, Hoppe D, Welzel T, Vermehren J, Herrmann E, Vermehren A, Friedrich-Rust M, Sarrazin C, Zeuzem S, Welker MW. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. *J Viral Hepat* 2016; **23**: 994-1002 [PMID: 27500382 DOI: 10.1111/jvh.12578]

105 **Bachofner JA**, Valli PV, Kröger A, Bergamin I, Künzler P, Baserga A, Braun D, Seifert B, Moncsek A, Fehr J, Semela D, Magenta L, Müllhaupt B, Terziroli Beretta-Piccoli B, Mertens JC. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. *Liver Int* 2017; **37**: 369-376 [PMID: 27678216 DOI: 10.1111/liv.13256]

106 **Chan PPY**, Levy MT, Shackel N, Davison SA, Prakoso E. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia. *Hepatobiliary Pancreat Dis Int* 2020; **19**: 541-546 [PMID: 32660841 DOI: 10.1016/j.hbpd.2020.06.013]

107 **Crismale JF**, Ahmad J. Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation. *World J Gastroenterol* 2019; **25**: 6799-6812 [PMID: 31885421 DOI: 10.3748/wjg.v25.i47.6799]

108 **Kahn JA**. The use of organs from hepatitis C virus-viremic donors into uninfected recipients. *Curr Opin Organ Transplant* 2020; **25**: 620-625 [PMID: 33105203 DOI: 10.1097/MOT.0000000000000826]

109 **Said A**, Weiss M, Varhelyi A, Farago R, Ballweg C, Rice J, Agarwal P, Fernandez L, Foley D. Utilization of hepatitis C viremic donors for liver transplant recipients without hepatitis C. A veterans transplant center report. *Transpl Infect Dis* 2020: e13466 [PMID: 32931616 DOI: 10.1111/tid.13466]

110 **Bohorquez H**, Bugeaud E, Bzowej N, Scheuermann J, Hand J, Bruce D, Carmody I, Cohen A, Joshi S, Seal J, Sonnier D, Therapondos G, Girgrah N, Anders S, Loss GE. Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care. *Liver Transpl* 2020 [PMID: 33098277 DOI: 10.1002/lt.25925]

111 **Boettler T**, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, Berg T. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. *JHEP Rep* 2020; **2**: 100113 [PMID: 32289115 DOI: 10.1016/j.jhepr.2020.100113]

112 **Fix OK**, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. *Hepatology* 2020; **72**: 287-304 [PMID: 32298473 DOI: 10.1002/hep.31281]

113 **Pokorska-Śpiewak M**, Śpiewak M. Management of hepatitis C in children and adolescents during COVID-19 pandemic. *World J Hepatol* 2020; **12**: 485-492 [PMID: 32952875 DOI: 10.4254/wjh.v12.i8.485]

**Footnotes**

**Conflict-of-interest statement:** Dr. Balistreri was an investigator for ABBVIE, GILEAD, and MERCK clinical trials; Dr. Rogers has no conflicts of interest to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** December 21, 2020

**First decision:** January 10, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Han GR **S-Editor:** Zhang H **L-Editor: P-Editor:**

**Table 1 Completed studies of direct acting antivirals regimens in children and adolescents**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Participant age in years (*n*)** | **HCV genotype** | **Therapy (duration)** | **SVR12 (%)** |
| Balistreri *et al*[50] | 2016 | 12-17 (100) | 1 | Ledipasvir 90 mg + sofosbuvir 400 mg (12 wk) | 98 |
| Wirth *et al*[51] | 2017 | 12-17 (52) | 2 or 3 | Sofosbuvir 400 mg + ribavirin (variable) | 98 |
| Hashmi *et al*[52] | 2017 | 5-18 (35) | 1 or 3 | Sofosbuvir 400 mg + ribavirin (variable) | 97 |
| El-Khayat *et al*[53] | 2018 | 12-17 (144) | 1, 4-6 | Ledipasvir 45 mg + sofosbuvir 200 mg (12 wk) | 99 |
| Murray *et al*[54] | 2018 | 6-11 (90) | 1 | Ledipasvir 45 mg + sofosbuvir 200 mg (12 wk) | 98 |
| El-Karaksy *et al*[55] | 2018 | 12-18 (40) | 4 | Ledipasvir 90 mg + sofosbuvir 400 mg (12 wk) | 100 |
| Leung *et al*[56] | 2018 | 12-17 (38) | 1 or 4 | Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin (variable) | 100 |
| Alkaaby *et al*[57] | 2018 | 7-18 (22) |  | Ledipasvir + sofosbuvir +/- ribavirin (variable) | 91 |
| Tucci *et al*[58] | 2018 | 0.5 (1) | 4 | Ledipasvir 22.5 mg + sofosbuvir 100 mg (12 wk) | 100 |
| El-Shabrawi *et al*[59] | 2018 | 6-12 (20) | 4 | Ledipasvir 45 mg + sofosbuvir 200 mg (12 wk) | 95 |
| El-Shabrawi *et al*[60] | 2018 | 12-17 (10) | 1-6 | Sofosbuvir 400 mg + daclatasvir 60 mg (8 wk) | 100 |
| Yakoot *et al*[61] | 2018 | 12-17 (30) | 4 | Sofosbuvir + daclatasvir (12 wk) | 97 |
| Quintero *et al*[62] | 2019 | 6-18 (9) | 1 or 4 | Ledipasvir + sofosbuvir (variable) | 100 |
| Ghaffar *et al*[63] | 2019 | 8-18 (40) | 4 | Sofosbuvir + daclatasvir (variable) | 97.5 |
| Fouad *et al*[64] | 2019 | 11-17.5 (51) | 4 | Ledipasvir 90 mg + sofosbuvir 400 mg (12 wk) | 100 |
| Ohya *et al*[65] | 2019 | 10-13 (3) | 1b | Ombitasvir + paritaprevir + ritonavir (12 wk)  Or glecaprevir + pibrenastavir (8 wk) | 100 |
| El-Shabrawi *et al*[66] | 2019 | 8-17 (20) | 4 | Sofosbuvir + Daclatasvir (12 wk) | 100 |
| Serranti *et al*[67] | 2019 | 12-17 (14) | 1 | Ledipasvir 90 mg + sofosbuvir 400 mg (8 wk) | 100 |
| Marascio *et al*[68] | 2019 | 13, 16 (2) | 4 | Ledipasvir 90 mg + sofosbuvir 400 mg (12 wk) | 100 |
| Fouad *et al*[69] | 2020 | 12-18 (46) | not performed | Ledipasvir 180 mg + sofosbuvir 400 mg (12 wk) | 98 |
| Kamal *et al*[70] | 2020 | 3-6 (22) | 4 | Ledipasvir 45 mg + sofosbuvir 200 mg (8 or 12 wk) | 100 |
| El-Araby *et al*[71] | 2020 | 9-12 (100) | 4 | Ledipasvir 90 mg + sofosbuvir 400 mg (12 wk) | 100 |
| Rosenthal *et al*[72] | 2020 | 3-11 (54) | 1 or 4 | Sofosbuvir 400 mg + ribavirin (variable) | 98 |
| Schwarz *et al*[73] | 2020 | 3-< 6 (34) | 1 or 4 | Ledipasvir + sofosbuvir (variable) | 97 |
| Jonas *et al*74] | 2020 | 12-17 (47) | 1-4 | Glecaprevir 300 mg + pibrentasvir 120 mg (8-16 wk) | 100 |
| Wirth *et al*[75] | 2020 | 3-17 (57) | 1 or 4 | Elbasvir + grazoprevir (12 wk) | 100 |
| Sokal *et al*[76] | 2020 | 3-17 (216) | 1-4, 6 | Sofosbuvir + velpatasvir (12 wk) | 92 |
| Behairy *et al*[77] | 2020 | 4-10 (30) | 4 | Ledipasvir 45 mg + sofosbuvir 200 mg (8 wk) | 100 |

Table adapted from Squires *et al*[17]. HCV: Hepatitis C virus.